Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer
- 1 March 1992
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 10 (1) , 43-44
- https://doi.org/10.1007/bf01275480
Abstract
Fourteen consecutive female patients with metastatic breast cancer received a total of 31 courses of fazarabine at a dose of 2 mg/m2/hour×72 hours (48 mg/m2/day×3) as a continuous infusion. There were no responses seen, although one patient achieved stability of her disease for five courses. Because of encouragingin vitro results and the primarily hematologic dose-limiting toxicity, further study in combination with colony stimulating growth factors might be of interest.Keywords
This publication has 4 references indexed in Scilit:
- Arabinosyl-5-azacytosine: A novel nucleoside entering clinical trialsInvestigational New Drugs, 1987
- The synthesis and antitumor activity of arabinosyl-5-azacytosineBiochemical Pharmacology, 1977
- Combination Chemotherapy for Advanced Breast Cancer: Response and Effect on SurvivalAnnals of Internal Medicine, 1976